Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 24 - DocsLib

sign in sign up

<<

Home , Abitesartan, Adaprolol, Amosulalol, Anipamil, Barnidipine, Brimonidine

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 1

16.1.9 Documentation of Statistical Methods 3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

67$7,67,&$/$1$/<6,63/$1

7LWOH$5DQGRPL]HG'RXEOHEOLQG3ODFHERFRQWUROOHG6WXG\WR(YDOXDWHWKH (IIHFWRI$0*RQ([HUFLVH7LPH'XULQJD7UHDGPLOO7HVWLQ6XEMHFWV:LWK 6WDEOH$QJLQD $0* 3URWRFRO1XPEHU

9HUVLRQ 9HUVLRQ

'DWH -DQXDU\

$XWKRUV PPD

1&71XPEHU 7KLV1&7QXPEHUKDVEHHQDSSOLHGWRWKHGRFXPHQW IRUSXUSRVHVRISRVWLQJRQFOLQLFDOWULDOVJRY 3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

7DEOHRI&RQWHQWV

7DEOHRI$EEUHYLDWLRQV

,QWURGXFWLRQ

2EMHFWLYHV 3ULPDU\ 6HFRQGDU\ 6DIHW\

6WXG\2YHUYLHZ 6WXG\'HVLJQ 6DPSOH6L]H

6WXG\(QGSRLQWVDQG&RYDULDWHV 6WXG\(QGSRLQWV 3ULPDU\(QGSRLQW 6HFRQGDU\(QGSRLQWV 6DIHW\(QGSRLQWV 3ODQQHG&RYDULDWHV

+\SRWKHVHV

'HILQLWLRQV 6WXG\'DWHV 6WXG\3RLQWVRI5HIHUHQFH %DVHOLQHDQG'HPRJUDSKLFV (IILFDF\(QGSRLQWV 6DIHW\(QGSRLQWV

$QDO\VLV6XEVHWV )XOO$QDO\VLV6HW 6DIHW\$QDO\VLV6HW (IILFDF\$QDO\VLV6HW 3HU3URWRFRO6HW 6XEJURXS$QDO\VHV

,QWHULP$QDO\VLVDQG(DUO\6WRSSLQJ*XLGHOLQHV

'DWD6FUHHQLQJDQG$FFHSWDQFH *HQHUDO3ULQFLSOHV 'DWD+DQGOLQJDQG(OHFWURQLF7UDQVIHURI'DWD +DQGOLQJRI0LVVLQJDQG,QFRPSOHWH'DWD 0LVVLQJDQG,QFRPSOHWH'DWHV 'HWHFWLRQRI%LDV 2XWOLHUV 'LVWULEXWLRQDO&KDUDFWHULVWLFV

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

9DOLGDWLRQRI6WDWLVWLFDO$QDO\VHV

6WDWLVWLFDO0HWKRGVRI$QDO\VLV *HQHUDO3ULQFLSOHV 6XEMHFW$FFRXQWDELOLW\ ,PSRUWDQW3URWRFRO'HYLDWLRQV 'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV (IILFDF\$QDO\VHV $QDO\VHVRI3ULPDU\(IILFDF\(QGSRLQW $QDO\VHVRI6HFRQGDU\(IILFDF\(QGSRLQWV 6DIHW\$QDO\VHV $GYHUVH(YHQWV &ROXPELD6XLFLGH6HYHULW\5DWLQJ6FDOH &6656 /DERUDWRU\7HVW5HVXOWV 9LWDO6LJQV $QWLERG\)RUPDWLRQ ([SRVXUHWR&RQFRPLWDQW0HGLFDWLRQ 3KDUPDFRNLQHWLF$QDO\VLV $GGLWLRQDO6DIHW\(QGSRLQWVIRU&RXQWU\6SHFLILF6XSSOHPHQW &RXQWULHV

&KDQJHV)URP3URWRFROVSHFLILHG$QDO\VHV

/LWHUDWXUH&LWDWLRQV5HIHUHQFHV

'DWD1RW&RYHUHGE\7KLV3ODQ

$SSHQGLFHV

/LVWRI7DEOHV 7DEOH6XPPDU\RI(IILFDF\(QGSRLQWVDQG$QDO\VLV0HWKRGV

/LVWRI$SSHQGLFHV $SSHQGL[$3RVWEDVHOLQH6WXG\9LVLWV $SSHQGL[%7HFKQLFDO'HWDLODQG6XSSOHPHQWDO,QIRUPDWLRQ5HJDUGLQJ 6WDWLVWLFDO3URFHGXUHVDQG3URJUDPV $SSHQGL[&5HIHUHQFH9DOXHV7R[LFLW\*UDGHV $SSHQGL['&RQFRPLWDQW0HGLFDWLRQV

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

7DEOHRI$EEUHYLDWLRQV

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

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

,QWURGXFWLRQ 7KHSXUSRVHRIWKLV6WDWLVWLFDO$QDO\VLV3ODQ 6$3 LVWRSURYLGHGHWDLOVRIWKHVWDWLVWLFDO DQDO\VHVWKDWKDYHEHHQRXWOLQHGZLWKLQ3URWRFRO$PHQGPHQWVDQGDVVRFLDWHG&RXQWU\ 6SHFLILF6XSSOHPHQWIRU$0*6WXG\GDWHG2FWREHUDQG 1RYHPEHUUHVSHFWLYHO\7KHVFRSHRIWKLVSODQLQFOXGHVWKHSULPDU\DQGILQDO DQDO\VHVWKDWDUHSODQQHGDQGZLOOEHH[HFXWHGE\WKH%LRVWDWLVWLFVGHSDUWPHQWXQOHVV RWKHUZLVHVSHFLILHG

2EMHFWLYHV 3ULPDU\ 7RHYDOXDWHWKHHIIHFWRI$0*FRPSDUHGWRSODFHERRQH[HUFLVHFDSDFLW\LQVXEMHFWV ZLWKVWDEOHDQJLQDDVPHDVXUHGE\WRWDOH[HUFLVHWLPH 7(7 GXULQJDQH[HUFLVHWUHDGPLOO WHVW (77

6HFRQGDU\ 7RHYDOXDWHWKHHIIHFWRI$0*FRPSDUHGWRSODFHERGXULQJDQ(77RQWKHWLPHWR WKHRQVHWRI

x ([HUFLVHLQGXFHGDQJLQD x 67VHJPHQWGHSUHVVLRQ

6DIHW\ 7RHYDOXDWHWKHVDIHW\DQGWROHUDELOLW\RI$0*LQDSRSXODWLRQZLWKVWDEOHDQJLQD

6WXG\2YHUYLHZ 6WXG\'HVLJQ 7KLVLVDSKDVHDPXOWLFHQWHUUDQGRPL]HGGRXEOHEOLQGSODFHERFRQWUROOHGVWXG\LQ VXEMHFWVZLWKVWDEOHDQJLQD$WOHDVWVXEMHFWVZLOOEHUDQGRPL]HGLQDUDWLRWR UHFHLYHHLWKHUDVLQJOHGRVHRI$0*PJRUSODFHERLQWUDYHQRXVO\SULRUWR FRPSOHWLQJDQ(775DQGRPL]DWLRQZLOOEHVWUDWLILHGE\WKH7(7DYHUDJHRIWKH TXDOLI\LQJVFUHHQLQJ(77V PLQXWHVRUPLQXWHV 7UHDWPHQWJURXSZLOOEH EOLQGHGWRWKHLQYHVWLJDWRUVXEMHFWVDQGWKH$PJHQVWXG\WHDP

6DPSOH6L]H 7KHSULPDU\HQGSRLQWLVWKHFKDQJHIURPEDVHOLQHLQ7(7$VVXPLQJEHWZHHQVXEMHFW VWDQGDUGGHYLDWLRQIRUFKDQJHIURPEDVHOLQHLQH[HUFLVHGXUDWLRQRIVHFRQGVZLWKD SODQQHGVWXG\VL]HRIDWOHDVWVXEMHFWVLQHDFKJURXSDQGDGLIIHUHQFHLQFKDQJHIURP EDVHOLQHLQH[HUFLVHGXUDWLRQRIVHFRQGVEHWZHHQ$0*JURXSDQGSODFHERJURXS WKHUHLVDQSUREDELOLW\ SRZHU WKDWWKHORZHUERXQGRIWKHFRQILGHQFHLQWHUYDO

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

&, ZLOOH[FHHGVHFRQGV$PDUJLQODUJHUWKDQVHFRQGVEHWZHHQJURXSVZDV UHTXLUHGWRDFFRPPRGDWHWKHSRVVLELOLW\RIPRUHWKDQVHFRQG XSWR GLIIHUHQFH DOORZHGLQTXDOLI\LQJ7(7VIRULQGLYLGXDOVXEMHFWV%HFDXVHRIWKLVZLWKLQVXEMHFW7(7 YDULDWLRQDPD[LPXP7(7GLIIHUHQFHRIVHFRQGVEHWZHHQWKH$0*JURXSDQG SODFHERJURXSZDVFRQVLGHUHGUHDVRQDEOHLQWKLVVWXG\$PDUJLQRIVHFRQGVZDV VHOHFWHGZKLFKFRUUHVSRQGVWRWKHPDUJLQXVHGLQSUHYLRXVVWXG\WHVWLQJDFRPSDUDEOH K\SRWKHVLV 3DWWHUVRQHWDO 7ZHQW\QLQHVXEMHFWVDUHQHHGHGLQHDFKJURXSLI FRQVLGHULQJGURSRXW

:KHQDSSUR[LPDWHO\VXEMHFWVKDYHEHHQHQUROOHG$PJHQPD\FRQGXFWDEOLQGHG VDPSOHVL]HHVWLPDWLRQDQGPD\FKRRVHWRDOWHUWKHVDPSOHVL]HEDVHGRQWKHEOLQGHG YDULDQFHLQWKHSRROHGWUHDWPHQWJURXSV

6WXG\(QGSRLQWVDQG&RYDULDWHV 6WXG\(QGSRLQWV 3ULPDU\(QGSRLQW x &KDQJHIURPEDVHOLQHLQ7(7

6HFRQGDU\(QGSRLQWV x 'XULQJWKH(77 R 7LPHWRRQVHWRIH[HUFLVHLQGXFHGDQJLQD R 7LPHWRRQVHWRIPP67VHJPHQWGHSUHVVLRQ

6DIHW\(QGSRLQWV x $GYHUVHHYHQWVDQGGLVHDVHUHODWHGHYHQWV x &KDQJHVLQYLWDOVLJQV

)RU&RXQWU\6SHFLILF6XSSOHPHQWFRXQWULHVRQO\

R 0D[LPXPFKDQJHLQ67VHJPHQWGHSUHVVLRQ PP IURPEDVHOLQH R 0D[LPXPKHDUWUDWH +5 R 0D[LPXPFKDQJHLQV\VWROLFEORRGSUHVVXUH 6%3 IURPEDVHOLQH

3ODQQHG&RYDULDWHV 7KHVWUDWLILFDWLRQIDFWRURIEDVHOLQH7(7 RUPLQXWHV ZLOOEHLQFOXGHGDVD FRYDULDWHLQWKHSULPDU\DQDO\VLVRIWKHHIILFDF\HQGSRLQWV

6WUDWLILFDWLRQIDFWRUZLOOXVHWKHYDOXHVXVHGIRUUDQGRPL]DWLRQXQOHVVRWKHUZLVHQRWHG

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

+\SRWKHVHV 7KHSULPDU\HQGSRLQWRIWKHVWXG\ZLOOEHWHVWHGIRU$0*FRPSDUHGWRSODFHERZLWK W\SH,HUURU

x 1XOO+\SRWKHVLV,QVXEMHFWVZLWKDQJLQD$0*GRHVVLJQLILFDQWO\GHFUHDVH H[HUFLVHFDSDFLW\ E\DWOHDVWVHFRQGV DVPHDVXUHGE\FKDQJHIURP EDVHOLQHLQWRWDOH[HUFLVHWLPHFRPSDUHGWRSODFHERDQGWKDWWKHWUXHWUHDWPHQW GLIIHUHQFHLQFKDQJHIURPEDVHOLQHLQ7(7LVVHFRQGVRUPRUH ZRUVH x $OWHUQDWLYH+\SRWKHVLV,QVXEMHFWVZLWKDQJLQD$0*GRHVQRWGHFUHDVH H[HUFLVHFDSDFLW\DVPHDVXUHGE\FKDQJHIURPEDVHOLQHLQWRWDOH[HUFLVHWLPH FRPSDUHGWRSODFHERDQGWKDWWKHGLIIHUHQFHLQFKDQJHIURPEDVHOLQHLQ7(7LI DQ\LVOHVVWKDQDVHFRQGGHFUHDVH

'HILQLWLRQV

6WXG\'DWHV (QUROOPHQW'DWH

(QUROOPHQW'DWHLVGHILQHGDVWKHUDQGRPL]DWLRQGDWH

5DQGRPL]DWLRQ'DWH

5DQGRPL]DWLRQ'DWHLVGHILQHGDVWKHGDWHVXEMHFWZDVDOORFDWHGWRDWUHDWPHQWJURXS

)LUVW,3'RVH'DWH

)LUVW,3'RVH'DWHLVWKHGDWHRQZKLFKDVXEMHFWLVDGPLQLVWHUHGWKHILUVWGRVHRI,3 IROORZLQJUDQGRPL]DWLRQ)RUVXEMHFWVZKRDUHUDQGRPL]HGEXWQRWGRVHGZLWK,3ILUVW GRVHGDWHLVPLVVLQJ

6XEMHFWOHYHO(QGRI6WXG\ (26 'DWH

(QGRIVWXG\IRUHDFKVXEMHFWLVGHILQHGDVWKHODVWGDWHRQZKLFKWKHVXEMHFWODVW FRPSOHWHGDSURWRFROVSHFLILHGSURFHGXUH7KHGDWHZLOOEHUHFRUGHGRQWKH(QGRI6WXG\ &5)SDJH

3ULPDU\&RPSOHWLRQ'DWH

7KHSULPDU\FRPSOHWLRQGDWHLVGHILQHGDVWKHGDWHWKHODVWVXEMHFWFRPSOHWHVWKHRQ VWXG\(77

6WXG\&RPSOHWLRQ'DWH

7KHVWXG\FRPSOHWLRQGDWHLVWKH(26GDWHRIWKHODVWVXEMHFWLQWKHVWXG\

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

6WXG\3RLQWVRI5HIHUHQFH

6WXG\'D\

6WXG\'D\LVGHILQHGDVWKHILUVW,3GRVHGDWH)RUVXEMHFWVZKRDUHUDQGRPL]HGEXW QRWGRVHG6WXG\'D\LVGHILQHGDVWKHGDWHRIUDQGRPL]DWLRQ

6WXG\'D\

6WXG\'D\LVGHILQHGDVWKHQXPEHURIGD\VIURP6WXG\'D\

%HIRUH6WXG\'D\

6WXG\'D\ 'DWHRI,QWHUHVW±'DWHRI6WXG\'D\

2QRUDIWHU6WXG\'D\

6WXG\'D\ 'DWHRI,QWHUHVW±'DWHRI6WXG\'D\

7KHUHIRUHWKHGD\SULRUWR6WXG\'D\LV

3RVWEDVHOLQH6WXG\9LVLW

6HH$SSHQGL[$

&RPSOHWLQJ6WXG\

$VXEMHFWLVGHILQHGDVFRPSOHWLQJVWXG\LIWKHSULPDU\UHDVRQIRUHQGLQJVWXG\LV ³&RPSOHWHG´

&RPSOHWLQJ,QYHVWLJDWLRQDO3URGXFW ,3

$VXEMHFWLVGHILQHGDVFRPSOHWLQJ,3LIWKHUHDVRQIRUHQGLQJ,3LV³&RPSOHWHG´

%DVHOLQHDQG'HPRJUDSKLFV

$JHDW(QUROOPHQW

6XEMHFWDJHDWHQUROOPHQWZLOOEHFROOHFWHGLQ\HDUVLQWKHFOLQLFDOGDWDEDVH

%DVHOLQH9DOXHV

%DVHOLQH7(7LVWKHDYHUDJHRIWKHTXDOLI\LQJVFUHHQLQJ(77V

,IVXEMHFWFRPSOHWHV&ROXPELD6XLFLGH6HYHULW\5DWLQJ6FDOH &6656 IRUPRQ6WXG\ 'D\WKHQDOOLQGLYLGXDOLWHPVIURP6WXG\'D\YLVLWZLOOEHXVHGDVEDVHOLQH,IVXEMHFW GRHVQRWFRPSOHWH&6656IRUPRQ6WXG\'D\WKHQWKHODVWFRPSOHWHGIRUPSULRUWR 6WXG\'D\ZLOOEHXVHG

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

)RUDOORWKHUYDULDEOHVXQOHVVRWKHUZLVHVSHFLILHGEDVHOLQHYDOXHVDUHGHILQHGDVWKH ODVWQRQPLVVLQJYDOXHEHIRUHWKHILUVWGRVHRI,3RUUDQGRPL]DWLRQGDWHIRUVXEMHFWVZKR QHYHUUHFHLYHG,3,QFDVHVZKHUHEDVHOLQHPHDVXUHPHQWVDUHWDNHQRQWKHVDPHGD\ DVWKHILUVW,3GRVHGDWHLWZLOOEHDVVXPHGWKDWWKHVHPHDVXUHPHQWVDUHWDNHQSULRUWR ,3EHLQJDGPLQLVWHUHG

%0,

6XEMHFW¶V%0,ZLOOEHGHULYHGLQNJPLQWKHFOLQLFDOGDWDEDVH

(IILFDF\(QGSRLQWV &KDQJHIURPEDVHOLQHLQ7(7

&KDQJHIURPEDVHOLQHLQ7(7 7(7IURPRQVWXG\(77SRVWUDQGRPL]DWLRQ EDVHOLQH7(7

7LPHWR(YHQW

7LPHWRHYHQW RQVHWRIDQJLQDPP67VHJPHQWGHSUHVVLRQ LVGHILQHGDVWKHWLPH VXEMHFWUHFHLYHG,3WRWKHWLPHRIHYHQWRQVHW

7LPHWRHYHQW HYHQWRQVHWWLPH±WLPHUHFHLYHGLQYHVWLJDWLRQDOSURGXFW

,IQRHYHQWRFFXUVWKHQVXEMHFWZLOOEHFHQVRUHGDWWKH(77VWRSWLPH

6DIHW\(QGSRLQWV 7UHDWPHQW(PHUJHQW$GYHUVH(YHQW

(YHQWVFDWHJRUL]HGDVDGYHUVHHYHQWV $(V VWDUWLQJRQRUDIWHUILUVWGRVHRI,3DV GHWHUPLQHGE\WKHIODJLQGLFDWLQJLIWKH$(VVWDUWHGSULRUWRWKHILUVWGRVHRQWKH(YHQWV &5)DQGXSWRDQGLQFOXGLQJGD\VDIWHUWKHHQGRI,3RUHQGRIVWXG\ZKLFKHYHU FRPHVILUVW

6HULRXVDGYHUVHHYHQWV 6$(V DUHHYHQWVFDWHJRUL]HGDV$(VWKDWDUHVWDUWLQJRQRU DIWHUILUVWGRVHRI,3DVGHWHUPLQHGE\WKHIODJLQGLFDWLQJLIWKHDGYHUVHHYHQWVWDUWHG SULRUWRWKHILUVWGRVHRIWKH(YHQWV&5)DQGXSWRDQGLQFOXGLQJGD\VDIWHUWKHHQGRI LQYHVWLJDWLRQDOSURGXFW

7UHDWPHQWHPHUJHQW'LVHDVHUHODWHG(YHQW

(YHQWVFDWHJRUL]HGDV'LVHDVHUHODWHG(YHQWV '5(V VWDUWLQJRQRUDIWHUILUVWGRVHRI LQYHVWLJDWLRQDOSURGXFWDVGHWHUPLQHGE\WKHIODJLQGLFDWHGLIWKHHYHQWVWDUWHGSULRUWR WKHILUVWGRVHRQWKH(YHQWV&5)DQGXSWRDQGLQFOXGLQJGD\VDIWHUWKHHQGRI LQYHVWLJDWLRQDOSURGXFW

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

6HULRXVGLVHDVHUHODWHGHYHQWVDUHHYHQWVDUHHYHQWVFDWHJRUL]HGDV'5(VWKDWDUH VWDUWLQJRQRUDIWHUILUVWGRVHRILQYHVWLJDWLRQDOSURGXFWDVGHWHUPLQHGE\WKHIODJ LQGLFDWLQJLIWKHHYHQWVWDUWHGSULRUWRWKHILUVWGRVHRQWKH(YHQWV&5)DQGXSWRDQG LQFOXGLQJGD\VDIWHUWKHHQGRILQYHVWLJDWLRQDOSURGXFW

0D[LPXP&KDQJHIURP%DVHOLQHLQ6%3

7KHPD[LPXPFKDQJHIURPEDVHOLQHLQ6%3LVFDOFXODWHGE\WKHPD[LPXPYDOXHRI 6%3DIWHUILUVWGRVHGDWHņEDVHOLQH6%3

0D[LPXP&KDQJHIURP%DVHOLQHLQ+5

7KHPD[LPXPFKDQJHIURPEDVHOLQHLQ+5LVFDOFXODWHGE\WKHPD[LPXPYDOXHRI +5 DIWHUILUVWGRVHGDWHņEDVHOLQH+5

0D[LPXP&KDQJHIURP%DVHOLQHLQ676HJPHQW'HSUHVVLRQ

7KHPD[LPXPFKDQJHIURPEDVHOLQHLQ676HJPHQW'HSUHVVLRQLVFDOFXODWHGE\WKH PD[LPXPYDOXHRI 676HJPHQW'HSUHVVLRQDIWHUILUVWGRVHņEDVHOLQH676HJPHQW 'HSUHVVLRQ

&ROXPELD6XLFLGH6HYHULW\5DWLQJ6FDOH &6656

7KH&6656LVDFOLQLFLDQUDWLQJRIVXLFLGDOEHKDYLRUDQGLGHDWLRQ7ZRYHUVLRQV GHSHQGLQJRQWKHW\SHRIYLVLWVZLOOEHXVHGLQWKLVVWXG\6FUHHQLQJDQG6LQFH/DVW9LVLW 7KH&6656FRQVLVWVRIDPD[LPXPRILWHPVWRHYDOXDWHVXLFLGDOEHKDYLRUDQG VXLFLGDOLGHDWLRQ

$QDO\VLV6XEVHWV )XOO$QDO\VLV6HW 7KH)XOO$QDO\VLV6HW )$6 LQFOXGHVDOOUDQGRPL]HGVXEMHFWV6XEMHFWVZLOOEHDQDO\]HG DFFRUGLQJWRWKHLUUDQGRPL]HGWUHDWPHQWUHJDUGOHVVRIWKHWUHDWPHQWUHFHLYHG

6DIHW\$QDO\VLV6HW 7KH6DIHW\$QDO\VLV6HW 6$6 LQFOXGHVDOOUDQGRPL]HGVXEMHFWVZKRUHFHLYHGDWOHDVW RQHGRVHRILQYHVWLJDWLRQDOSURGXFW)RUDOOVDIHW\DQDO\VHVVXEMHFWVZLOOEHJURXSHG DFFRUGLQJWRWKHDFWXDOWUHDWPHQWUHFHLYHG

(IILFDF\$QDO\VLV6HW 7KH(IILFDF\$QDO\VLV6HW ($6 XWLOL]HVWKH)$6DQGLQFOXGHVVXEMHFWVZKRUHFHLYHG,3 DQGFRPSOHWHGWKHH[HUFLVHWUHDGPLOOWHVWSRVWUDQGRPL]DWLRQ (77U 6XEMHFWVZLOOEH JURXSHGDFFRUGLQJWRWKHLUUDQGRPL]HGWUHDWPHQWUHJDUGOHVVRIWKHWUHDWPHQWUHFHLYHG

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

3HU3URWRFRO6HW 7KH3HU3URWRFRO6HW 336 XWLOL]HVWKH($6DQGLQFOXGHVVXEMHFWVZKRFRPSOHWHG,3RQ 6WXG\'D\DQGGRQRWKDYHLPSRUWDQWSURWRFROGHYLDWLRQVWKDWZLOOSRWHQWLDOO\LPSDFW SULPDU\DQDO\VLVRIHIILFDF\HQGSRLQWV6XEMHFWVZKRGHYLDWHIURPNH\HOLJLELOLW\FULWHULD LQFOXGLQJFXUUHQWO\SDUWLFLSDWLQJLQDQRWKHULQYHVWLJDWLRQDOGHYLFHRUGUXJVWXG\ H[FOXVLRQ FULWHULD DQGFDUGLRYDVFXODUFRQGLWLRQV H[FOXVLRQFULWHULD ZLOOEHH[FOXGHGIURPWKHDQDO\VLV

6XEJURXS$QDO\VHV 3ULPDU\DQGVHFRQGDU\DQDO\VHVZLOOEHSHUIRUPHGDFFRUGLQJWRWKHIROORZLQJVXEJURXSV EDVHOLQH7(7 PLQXWHVRUPLQXWHV UDQGRPL]DWLRQVWUDWDDJHJURXS DQGVH[

,QWHULP$QDO\VLVDQG(DUO\6WRSSLQJ*XLGHOLQHV $'DWD0RQLWRULQJ&RPPLWWHH '0& ZLOOUHYLHZDOODYDLODEOHVDIHW\GDWDSHULRGLFDOO\ 7KH'0&ZLOOKDYHDFFHVVWRVXEMHFWV¶LQGLYLGXDOWUHDWPHQWDVVLJQPHQWV7RPLQLPL]H WKHSRWHQWLDOLQWURGXFWLRQRIELDVWRWKHFRQGXFWRIWKHVWXG\PHPEHUVRIWKH'0&ZLOO QRWKDYHDQ\GLUHFWFRQWDFWZLWKVWXG\FHQWHUSHUVRQQHORUVXEMHFWV7KH'0&ZLOO FRPPXQLFDWHPDMRUVDIHW\FRQFHUQVDQGUHFRPPHQGDWLRQVUHJDUGLQJVWXG\PRGLILFDWLRQ RUWHUPLQDWLRQEDVHGRQWKHVDIHW\SDUDPHWHUVWR$PJHQLQDFFRUGDQFHZLWKWKH'0& FKDUWHU

5HFRUGVRIDOOPHHWLQJVZLOOEHPDLQWDLQHGE\WKH'0&IRUWKHGXUDWLRQRIWKHVWXG\ 5HFRUGVRIDOOPHHWLQJVZLOOEHVWRUHGLQWKH$PJHQRIILFLDOGRFXPHQWPDQDJHPHQW V\VWHPDWWKHFRQFOXVLRQRIWKHVWXG\)XUWKHUGHWDLOVDUHSURYLGHGLQWKH'0&FKDUWHU

1RLQWHULPDQDO\VLVLVSODQQHGIRUWKLVVWXG\H[FHSWIRUVDPSOHVL]HUHHVWLPDWLRQWKDWZLOO EHSHUIRUPHGRQWKHSRROHGVDPSOHDIWHUVXEMHFWVKDYHEHHQHQUROOHG$PJHQPD\ FKRRVHWRDOWHUWKHVDPSOHVL]HEDVHGRQWKHSRROHGYDULDQFHLQWKHRYHUDOOJURXS

'DWD6FUHHQLQJDQG$FFHSWDQFH *HQHUDO3ULQFLSOHV 7KHREMHFWLYHRIWKHGDWDVFUHHQLQJLVWRDVVHVVWKHTXDQWLW\TXDOLW\DQGVWDWLVWLFDO FKDUDFWHULVWLFVRIWKHGDWDUHODWLYHWRWKHUHTXLUHPHQWVRIWKHSODQQHGDQDO\VHV

'DWD+DQGOLQJDQG(OHFWURQLF7UDQVIHURI'DWD 7KH$PJHQ*OREDO6WXG\2SHUDWLRQV'DWD0DQDJHPHQW *62'0 GHSDUWPHQWZLOO SURYLGHDOOGDWDWREHXVHGLQWKHSODQQHGDQDO\VHV7KLVVWXG\ZLOOXVHWKH5$9( GDWDEDVH7KHGDWDEDVHZLOOEHVXEMHFWHGWRHGLWFKHFNRXWOLQHGLQWKH'DWD

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

0DQDJHPHQW3ODQ '03 &HQWUDOODERUDWRU\3.DQWLERG\ELRPDUNHUVDGMXGLFDWHG HYHQWVDQG(&*GDWDLVRXWVLGHRI5$9(GDWDEDVH$OOWKHGDWDVHWVWREHXVHGIRU SODQQHGDQDO\VHVZLOOEHUHFHLYHGIURP*62'0GHSDUWPHQW$GGLWLRQDOGHWDLOVZLOOEH SURYLGHGLQWKH'03DQG'DWD7UDQVIHU3ODQ '73

+DQGOLQJRI0LVVLQJDQG,QFRPSOHWH'DWD 6XEMHFWVPD\PLVVVSHFLILFGDWDSRLQWVIRUDYDULHW\RIFDXVHV,QJHQHUDOGDWDFRXOGEH PLVVLQJGXHWRDVXEMHFW¶VHDUO\ZLWKGUDZDOIURPVWXG\DPLVVHGYLVLWRULQDELOLW\WR HYDOXDWHDQHQGSRLQWDWDSDUWLFXODUSRLQWLQWLPH0LVVLQJDVVHVVPHQWDWEDVHOLQHRU RQVWXG\ZLOOQRWEHLPSXWHG

0LVVLQJDQG,QFRPSOHWH'DWHV 0LVVLQJDQGSDUWLDOO\PLVVLQJGDWHVIRUWKHIROORZLQJSDUDPHWHUVZLOOEHTXHULHG,Q JHQHUDOWKHDOJRULWKPIRULPSXWLQJPLVVLQJGDWHVZLOOXVHWKHORJLFEHORZ8QOHVV RWKHUZLVHVSHFLILHG6WXG\'D\ZLOOEHWKHILUVWGRVHGDWHRUUDQGRPL]DWLRQGDWHIRU VXEMHFWVZKRQHYHUUHFHLYHG,3

x ,IWKH\HDUDQGPRQWKDUHWKHVDPHDV6WXG\'D\EXWWKHGD\SDUWLVPLVVLQJ WKHGD\ZLOOEHVHWWRWKHVWRIWKHPRQWKRI6WXG\'D\ x ,IWKH\HDULVWKHVDPHDV6WXG\'D\EXWWKHGD\DQGPRQWKDUHPLVVLQJWKH GD\DQGPRQWKZLOOEHVHWWRWKHVWRI-DQXDU\RI6WXG\'D\ x ,IWKH\HDUDQGGD\DUHWKHVDPHDV6WXG\'D\EXWPRQWKLVPLVVLQJWKHPRQWK ZLOOEHVHWWR-DQXDU\RI6WXG\'D\ x ,IWKHPRQWKDQGGD\DUHWKHVDPHDV6WXG\'D\EXW\HDULVPLVVLQJWKH\HDU ZLOOEHUHVHWWRWKH\HDURI6WXG\'D\ x ,IDQ\RIWKHUHVXOWLQJGDWHVDUHSULRUWRUHIHUHQFHGDWHWKHLPSXWHGGDWHZLOOEH UHVHWWRWKHUHIHUHQFHGDWH x ,IGD\PRQWKDQG\HDUDUHDOOPLVVLQJQRLPSXWDWLRQZLOOEHDSSOLHG

3DUWLDOPLVVLQJ$(DQGFRQFRPLWDQWPHGLFDWLRQVWDUWGDWHVZLOOEHLPSXWHGXVLQJWKH DOJRULWKPDERYHZLWKWKH6WXG\'D\EHLQJWKHILUVWGRVHGDWH)RUVXEMHFWVZKRDUH UDQGRPL]HGEXWQRWGRVHG6WXG\'D\LVGHILQHGDVWKHGDWHRIUDQGRPL]DWLRQ$(V WKDWRFFXUUHGEHIRUHILUVWGRVHDVLQGLFDWHGE\³'LGHYHQWVWDUWEHIRUHILUVWGRVHRI LQYHVWLJDWLRQDOSURGXFW´LVPDUNHGµ<¶ZLOOQRWEHLPSXWHG

'HWHFWLRQRI%LDV 7KLVVWXG\KDVEHHQGHVLJQHGWRPLQLPL]HSRWHQWLDOELDVE\DOORFDWLQJWUHDWPHQWJURXSV UDQGRPO\DVVHVVLQJHQGSRLQWVDQGKDQGOLQJZLWKGUDZDOVZLWKRXWNQRZOHGJHRIWKH WUHDWPHQW2WKHUIDFWRUVWKDWPD\ELDVWKHUHVXOWVRIWKHVWXG\LQFOXGH

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

x LPSRUWDQWSURWRFROGHYLDWLRQVOLNHO\WRLPSDFWWKHDQDO\VLVDQGLQWHUSUHWDWLRQRI WKHHIILFDF\HQGSRLQWV x LQDGYHUWHQWEUHDNLQJRIWKHEOLQGEHIRUHIRUPDOXQEOLQGLQJ x LQYHVWLJDWLRQDOSURGXFWGRVLQJQRQFRPSOLDQFH x WKHWLPLQJRIDQGUHDVRQVIRUHDUO\ZLWKGUDZDOIURPWUHDWPHQWDQGIURPVWXG\

7KHLQFLGHQFHRIWKHVHIDFWRUVPD\EHDVVHVVHG,PSRUWDQWSURWRFROGHYLDWLRQVZLOOEH OLVWHGDQGRUWDEXODWHGLQWKHFOLQLFDOVWXG\UHSRUW &65 ,IQHFHVVDU\WKHLQFLGHQFHRI RWKHUIDFWRUVZLOOEHWDEXODWHG

$Q\EUHDNLQJRIWKHEOLQGIRULQGLYLGXDOVXEMHFWVSULRUWRIRUPDOXQEOLQGLQJRIWKHVWXG\ZLOO EHGRFXPHQWHGLQWKH&65

2XWOLHUV +LVWRJUDPVZLOOEHH[DPLQHGWRLGHQWLI\RXWOLHUVLQDQ\RIWKHFRQWLQXRXVYDULDEOHVXVHG LQWKHDQDO\VHV8QH[SHFWHGDQGRUXQH[SODLQHGYDOXHVLQFDWHJRULFDOGDWDZLOOEH LGHQWLILHGE\XWLOL]LQJIUHTXHQF\WDEOHV

([WUHPHGDWDSRLQWVZLOOEHLGHQWLILHGGXULQJEOLQGHGUHYLHZRIWKHGDWDEHIRUHILQDO GDWDEDVHORFN7KHVHGDWDSRLQWVZLOOEHUHYLHZHGDQGTXHULHGSHUWKHGDWD PDQDJHPHQWRUFOLQLFDOOLVWLQJUHYLHZSODQV([WUHPHYDOXHVZLOOQRWEHH[FOXGHGIURP WKHDQDO\VHV

'LVWULEXWLRQDO&KDUDFWHULVWLFV 6WDWLVWLFDODVVXPSWLRQVIRUWKHSULPDU\DQGVHFRQGDU\HQGSRLQWDQDO\VHVZLOOEH DVVHVVHG&RQWLQXRXVHQGSRLQWVRIFKDQJHIURPEDVHOLQHLQ7(7ZLOOEHDQDO\]HGXQGHU QRUPDOLW\DVVXPSWLRQ,IWKHDVVXPSWLRQVIRUWKHSULPDU\DQDO\VLVDUHQRWPHWWKHQ VXLWDEOHWUDQVIRUPDWLRQPHWKRGV HJORJWUDQVIRUP ZLOOEHDSSOLHG

9DOLGDWLRQRI6WDWLVWLFDO$QDO\VHV 3URJUDPVZLOOEHGHYHORSHGDQGPDLQWDLQHGDQGRXWSXWZLOOEHYHULILHGLQDFFRUGDQFH ZLWKFXUUHQWULVNEDVHGTXDOLW\FRQWUROSURFHGXUHV

7DEOHVILJXUHVDQGOLVWLQJVZLOOEHSURGXFHGZLWKYDOLGDWHGVWDQGDUGPDFURSURJUDPV ZKHUHVWDQGDUGPDFURVFDQSURGXFHWKHVSHFLILHGRXWSXWV

7KHSURGXFWLRQHQYLURQPHQWIRUVWDWLVWLFDODQDO\VHVFRQVLVWVRI$PJHQVXSSRUWHG YHUVLRQVRIVWDWLVWLFDODQDO\VLVVRIWZDUHIRUH[DPSOHWKH6$66\VWHPYHUVLRQRU ODWHU

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

6WDWLVWLFDO0HWKRGVRI$QDO\VLV *HQHUDO3ULQFLSOHV 7KHSULPDU\DQDO\VLVWRHYDOXDWHWKHHIIHFWRI$0*FRPSDUHGWRSODFHERRQ H[HUFLVHFDSDFLW\LQVXEMHFWVZLWKVWDEOHDQJLQDDVPHDVXUHGE\7(7GXULQJDQ(77

7KH)$6ZLOOEHXVHGWRWDEXODWHGHPRJUDSKLFGDWDEDVHOLQHGLVHDVHFKDUDFWHULVWLFV DQGVXEMHFWGLVSRVLWLRQ7KH($6ZLOOLQFOXGHDOO)$6VXEMHFWVZKRUHFHLYHG,3DQG FRPSOHWHGWKH(77UDQGZLOOEHXVHGWRDQDO\]HWKHSULPDU\DQGVHFRQGDU\HQGSRLQWV LQFOXGLQJWKHFKDQJHIURPEDVHOLQHLQ7(7WLPHWRRQVHWRIPP67VHJPHQW GHSUHVVLRQDQGWLPHWRRQVHWRIH[HUFLVHLQGXFHGDQJLQD7KH6DIHW\$QDO\VLV6HWZLOO EHXVHGWRDQDO\]HVDIHW\HQGSRLQWV

6XPPDU\VWDWLVWLFVE\HDFKWUHDWPHQWJURXSZLOOEHWDEXODWHGDWHDFKYLVLW)RU FRQWLQXRXVHQGSRLQWVGHVFULSWLYHVWDWLVWLFVZLOOEHSURYLGHGLQFOXGLQJQXPEHURI VXEMHFWVPHDQPHGLDQVWDQGDUGGHYLDWLRQVWDQGDUGHUURUORZHUDQGXSSHUTXDUWLOHV PLQLPXPDQGPD[LPXP)RUFDWHJRULFDOHQGSRLQWVIUHTXHQF\DQGSHUFHQWDJHZLOOEH JLYHQ0LVVLQJGDWDZLOOQRWEHLPSXWHG

%DVHOLQHYDOXHIRUH[HUFLVHGXUDWLRQLVWKHDYHUDJHYDOXHRIWKHWZRTXDOLI\LQJ PHDVXUHPHQWVLQWKHVFUHHQLQJSHULRG

6XEMHFW$FFRXQWDELOLW\ 7KHQXPEHUDQGSHUFHQWRIVXEMHFWVZKRZHUHVFUHHQHGUDQGRPL]HGUHFHLYHG,3 UHFHLYHGSDUWLDORUQRQHFRPSOHWHGVWXG\GLVFRQWLQXHGVWXG\DQGUHDVRQVIRU GLVFRQWLQXLQJZLOOEHVXPPDUL]HGE\WUHDWPHQWJURXS

7KHQXPEHUDQGSHUFHQWRIVXEMHFWVUDQGRPL]HGZLOOEHWDEXODWHGE\VWXG\VLWH

.H\VWXG\GDWHVIRUWKHILUVWVXEMHFWHQUROOHGODVWVXEMHFWHQUROOHGODVWVXEMHFW¶VHQGRI VWXG\DQGODVWVXEMHFW¶V(77ZLOOEHSUHVHQWHG

'DWDDQDO\VLVZLOORFFXUDWWKHIROORZLQJWLPHSRLQWV

7KHSULPDU\DQDO\VLVZLOOWDNHSODFHDIWHUDOOVXEMHFWVKDYHFRPSOHWHGWKHRQVWXG\(77

7KHILQDODQDO\VLVZLOOWDNHSODFHDIWHUDOOVXEMHFWVKDYHFRPSOHWHGWKHVWXG\DQGDIWHU WKHILQDOGDWDEDVHORFN

,PSRUWDQW3URWRFRO'HYLDWLRQV ,PSRUWDQW3URWRFRO'HYLDWLRQV ,3'V FDWHJRULHVDUHGHILQHGE\WKHVWXG\WHDPEHIRUH WKHILUVWVXEMHFW¶VYLVLWDQGXSGDWHGGXULQJWKH,3'UHYLHZVWKURXJKRXWWKHVWXG\SULRUWR GDWDEDVHORFN7KHVHGHILQLWLRQVRI,3'FDWHJRULHVVXEFDWHJRU\FRGHVDQG

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

GHVFULSWLRQVZLOOEHXVHGGXULQJWKHFRXUVHRIWKHVWXG\(OLJLELOLW\GHYLDWLRQVDUHGHILQHG LQWKHSURWRFRO

'HPRJUDSKLFDQG%DVHOLQH&KDUDFWHULVWLFV 'HPRJUDSKLF LHDJHDJHJURXS EDVHGRQPHGLDQFXWSRLQW JHULDWULFDJHJURXS > DQG@VH[UDFHHWKQLFLW\ DQGEDVHOLQHGLVHDVHFKDUDFWHULVWLFVZLOOEH VXPPDUL]HGE\WUHDWPHQWJURXSDQGRYHUDOOXVLQJGHVFULSWLYHVWDWLVWLFV

,IPXOWLSOHUDFHVKDYHEHHQUHSRUWHGIRUDVXEMHFWWKHVXEMHFWZLOOEHFDWHJRUL]HGDV PXOWLSOHUDFH

7KHIROORZLQJEDVHOLQHFKDUDFWHULVWLFVZLOODOVREHVXPPDUL]HG

x :HLJKW NJ x +HLJKW FP x %RG\0DVV,QGH[ %0,NJP x 6\VWROLF%3 PP+J x 'LDVWROLF%3 PP+J x +HDUW5DWH EHDWVPLQ x %DVHOLQH7(7 VHFRQGV x &RQFRPLWDQWPHGLFDWLRQVRILQWHUHVW EHWDEORFNHUVQLWUDWHVFDOFLXP FKDQQHOEORFNHUVUDQROD]LQH$&(LQKLELWRUVDQGDQJLRWHQVLQUHFHSWRU EORFNHUV

(IILFDF\$QDO\VHV 'HWDLOHGSULPDU\VHFRQGDU\DQGVHQVLWLYLW\DQDO\VLVPHWKRGVDUHVXPPDUL]HGLQWKH WDEOHEHORZ

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

7DEOH6XPPDU\RI(IILFDF\(QGSRLQWVDQG$QDO\VLV0HWKRGV

3ULPDU\DQG6HFRQGDU\ (QGSRLQW $QDO\VLV0HWKRGV ($6 6HQVLWLYLW\$QDO\VLV0HWKRGV 3ULPDU\(QGSRLQW &KDQJHIURPEDVHOLQH x 3ULPDU\DQDO\VLV x $QDO\VLVRIFRYDULDQFH LQ7(7 VHFRQGV 7ZR:D\$129$PRGHO $1&29$ PRGHOZLWKWHUPVRI ZLWKWHUPVRIWUHDWPHQW WUHDWPHQWJURXSDQGEDVHOLQH JURXSDQGUDQGRPL]DWLRQ 7(7DVDFRQWLQXRXVPHDVXUH VWUDWD RU x 5HSHDWSULPDU\DQDO\VLVXVLQJ PLQXWHV WKH3HU3URWRFRO$QDO\VLV6HW x 5HSHDWSULPDU\DQDO\VLVE\ VXEJURXSVLQFOXGLQJEDVHOLQH 7(7UDQGRPL]DWLRQVWUDWDDJH JURXSDQGVH[ LIVDPSOHVL]H SHUPLWV

6HFRQGDU\(QGSRLQWV 7LPHWRRQVHWRI x 3ULPDU\DQDO\VLV.0 x 5HSHDWSULPDU\DQGVHFRQGDU\ H[HUFLVHLQGXFHG ORJUDQNWHVWVWUDWLILHGE\ DQDO\VHVXVLQJWKH3HU3URWRFRO DQJLQD VHFRQGV %DVHOLQH7(7VWUDWD $QDO\VLV6HW RUPLQXWH x 5HSHDWSULPDU\DQGVHFRQGDU\ 6HFRQGDU\DQDO\VLV&R[ DQDO\VHVE\VXEJURXSV 7LPHWRRQVHWRI SURSRUWLRQDOKD]DUG LQFOXGLQJEDVHOLQH7(7 PP67VHJPHQW PRGHOLQFOXGLQJ UDQGRPL]DWLRQVWUDWDDJHJURXS GHSUHVVLRQ VHFRQGV WUHDWPHQWJURXSDQG DQGVH[ LIVDPSOHVL]HSHUPLWV EDVHOLQH7(7DVD FRQWLQXRXVPHDVXUH LQFOXGHVDQJLQDUHODWHGV\PSWRPV

$QDO\VHVRI3ULPDU\(IILFDF\(QGSRLQW 7KHDQDO\VLVIRUWKHSULPDU\HQGSRLQWHYDOXDWLQJFKDQJHIURPEDVHOLQHLQ7(7ZLOOEH SHUIRUPHGXVLQJWKH($67KHSULPDU\K\SRWKHVLVLVWKDW$0*GRHVQRW VXEVWDQWLDOO\GHFUHDVHH[HUFLVHFDSDFLW\DVPHDVXUHGE\FKDQJHIURPEDVHOLQHLQ H[HUFLVHGXUDWLRQFRPSDUHGWRSODFHER LHWKHWUXHWUHDWPHQWGLIIHUHQFHLQFKDQJHIURP EDVHOLQHLQH[HUFLVHGXUDWLRQLVVHFRQGVRUPRUH

,QWKHSULPDU\DQDO\VLVWKHSULPDU\HQGSRLQWZLOOEHDQDO\]HGXVLQJDQ$129$PRGHO ZLWKWHUPVIRUWUHDWPHQWJURXSDQGEDVHOLQH7(7 RUPLQXWHV UDQGRPL]DWLRQ VWUDWD$GMXVWHGJURXSPHDQVIRUHDFKWUHDWPHQWJURXSVWDQGDUGHUURU&, GLIIHUHQFHRIJURXSPHDQVFRPSDUHGWRSODFHERDQGDVVRFLDWHG&,VZLOOEH WDEXODWHG,IWKHORZHUERXQGRIWKH&,RIWKHGLIIHUHQFHLVPRUHWKDQVHFRQGV WKHQWKHK\SRWKHVLVWKDW$0*GRHVQRWVXEVWDQWLDOO\GHFUHDVHH[HUFLVHGXUDWLRQZLOO EHVXSSRUWHG

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

6WDWLVWLFDODVVXPSWLRQVIRUWKHSULPDU\HQGSRLQWPHWKRGRIDQDO\VLVZLOOEHDVVHVVHG,I WKHDVVXPSWLRQVIRUWKHSULPDU\DQDO\VLVDUHQRWPHWWKHQQRQSDUDPHWULFPHWKRGVRU VXLWDEOHWUDQVIRUPDWLRQZLOOEHXWLOL]HG

6HQVLWLYLW\DQDO\VHVGHVFULEHGEHORZZLOOEHSHUIRUPHGIRUWKHSULPDU\HQGSRLQWXVLQJ WKH($6

x $QDQDO\VLVRIFRYDULDQFH $1&29$ PRGHOLQFOXGLQJWUHDWPHQWJURXSDQG EDVHOLQH7(7DVDFRQWLQXRXVPHDVXUH x 7KHSULPDU\DQDO\VLVZLOOEHUHSHDWHGXVLQJWKH336

7RDVVHVVLIWKHWUHDWPHQWHIIHFWYDULHVDFURVVVXEJURXSVRILQWHUHVWWKHSULPDU\ DQDO\VLVRIWKHSULPDU\HQGSRLQWZLOOEHUHSHDWHGDQGZLOOLQFOXGHDQLQWHUDFWLRQWHUP WUHDWPHQWJURXS VXEJURXS LQWKH$129$PRGHO,IDWUHDWPHQWJURXS VXEJURXS LQWHUDFWLRQLVREVHUYHGDWDVLJQLILFDQFHOHYHORIWKHQWKHSULPDU\DQDO\VLVPD\EH UHSHDWHGIRUHDFKOHYHORIWKHVXEJURXS,QDGGLWLRQUHDVRQVIRUVWRSSLQJWKH(77UZLOO EHVXPPDUL]HGE\WUHDWPHQWJURXSXVLQJWKH($6

$QDO\VHVRI6HFRQGDU\(IILFDF\(QGSRLQWV 7KHVHFRQGDU\HQGSRLQWVDUHWLPHWRRQVHWRIH[HUFLVHLQGXFHGDQJLQDDQGWLPHWRRQVHW RIPP67VHJPHQWGHSUHVVLRQ

)RUWLPHWRHYHQWHQGSRLQWVRQO\WKHILUVWRFFXUUHQFHZLOOEHFRQVLGHUHG,IQRHYHQWLV REVHUYHGGXULQJ(77UWKHQWKLVVXEMHFWZLOOEHFRQVLGHUHGDVFHQVRUHGDWWKHHQGRI (77U

.DSODQ0HLHUHVWLPDWHVRIWKHHYHQWIUHHWLPHWR67VHJPHQWGHSUHVVLRQDQGH[HUFLVH LQGXFHGDQJLQDZLOOEHFRPSXWHGDQGJUDSKLFDOO\GLVSOD\HGXVLQJWKH($6)RUHDFK HQGSRLQWDVWUDWLILHG RUPLQXWHUDQGRPL]DWLRQVWUDWD ORJUDQNWHVWVWDWLVWLFZLOOEH FDOFXODWHGWRFRPSDUHWKHWZRWUHDWPHQWJURXSVDWDVLJQLILFDQFHOHYHORI

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

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

6XPPDU\VWDWLVWLFV PHDQPHGLDQ44DQG&, RIWLPHWRHYHQWZLOOEH SURYLGHGE\WUHDWPHQWJURXS7KHQXPEHUDQGSHUFHQWDJHRIVXEMHFWVZLWKDQREVHUYHG HYHQWZLOODOVREHSURYLGHG

6HQVLWLYLW\DQDO\VHVGHVFULEHGEHORZZLOOEHSHUIRUPHGIRUWKHVHFRQGDU\HQGSRLQWV

x 5HSHDWWKHVHFRQGDU\DQDO\VLV &R[SURSRUWLRQDOKD]DUGVUHJUHVVLRQ XVLQJ EDVHOLQH7(7DVDFRQWLQXRXVPHDVXUH x 5HSHDWWKHSULPDU\DQGVHFRQGDU\DQDO\VLVXVLQJ336

6DIHW\$QDO\VHV $GYHUVH(YHQWV 7KH0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV 0HG'5$ YHUVLRQRUODWHUZLOOEH XVHGWRFRGHDOOHYHQWVFDWHJRUL]HGDV$(VDQG'LVHDVHUHODWHG(YHQWV '5(V WRD V\VWHPRUJDQFODVVDQGDSUHIHUUHGWHUP

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

6XEMHFWOHYHOGDWDPD\EHSURYLGHGLQVWHDGRIWDEOHVLIWKHVXEMHFWLQFLGHQFHLVORZ

6XEMHFWLQFLGHQFHRI'5(VZLOOEHVXPPDUL]HGIRUDOOWUHDWPHQWHPHUJHQW'5(VDQG IDWDO'5(V

&ROXPELD6XLFLGH6HYHULW\5DWLQJ6FDOH &6656 1RVWDWLVWLFDOWHVWLQJZLOOEHSHUIRUPHGRQ&66567KHQXPEHUDQGSHUFHQWDJHRI VXEMHFWVUHSRUWLQJDQ\VXLFLGDOLGHDWLRQDQGDQ\VXLFLGDOEHKDYLRUZLOOEHVXPPDUL]HG GHVFULSWLYHO\E\WUHDWPHQWJURXS6KLIWWDEOHRI&6656PD[LPXPVHYHULW\RIVXLFLGDO LGHDWLRQEHKDYLRUFRPSDUHGWREDVHOLQHZLOOEHSURYLGHGE\WUHDWPHQWJURXS

/DERUDWRU\7HVW5HVXOWV 6KLIWVWDEOHVRIWKHODERUDWRU\WR[LFLW\IRUVHOHFWHGODEDQDO\WHV DODQLQH DPLQRWUDQVIHUDVHDVSDUWDWHDPLQRWUDQVIHUDVHDONDOLQHSKRVSKDWDVHWRWDOELOLUXELQ FUHDWLQLQH EDVHGRQ&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV &7&$( JUDGH YHUVLRQ UHODWLYHWREDVHOLQHZLOOEHWDEXODWHGE\WUHDWPHQWJURXSIRUHQWLUHVWXG\

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

SHULRG,QWKHFDVHVZKHQ&7&$(JUDGLQJVFDOHVLQFOXGHQXPHULFUDQJHVLQFRPELQDWLRQ ZLWKFOLQLFDODVVHVVPHQW HJ3RWDVVLXP>+\SRNDOHPLD@ ODERUDWRU\WHVWUHVXOWVPD\EH VXPPDUL]HGEDVHGRQVWDQGDUGQRUPDOUDQJHVRUE\&7&$(JUDGHXWLOL]LQJ LQYHVWLJDWRU¶VLQSXW

6XPPDU\RIFKDQJHIURPEDVHOLQHIRUDEVROXWHQHXWURSKLOFRXQW $1& DODQLQH WUDQVDPLQDVH $/7 DVSDUWDWHDPLQRWUDQVIHUDVH $67 DQGFUHDWLQLQHZLOODOVREH SURYLGHG

$GGLWLRQDOOLYHUWHVWVXPPDU\WDEOHZLOOSURYLGHWKHQXPEHUDQGSHUFHQWDJHRIVXEMHFWV E\WUHDWPHQWJURXSIRUWKHIROORZLQJFDWHJRULHV

x $67DQG$/7 ![8/1![8/1![8/1![8/1UHVSHFWLYHO\ x $67RU$/7 ![8/1![8/1![8/1![8/1UHVSHFWLYHO\ x 7RWDO%LOLUXELQ ![8/1![8/1![8/1UHVSHFWLYHO\ x $/3 !8/1 x $/7RU$67![8/1DQG7RWDO%LOL[8/1DQG$/3 [8/1

9LWDO6LJQV 'HVFULSWLYHVXPPDULHVRIEORRGSUHVVXUHVDQG+5ZLOOEHSURYLGHGDWEDVHOLQHDQGDW HDFKVWXG\YLVLW,QDGGLWLRQEORRGSUHVVXUHVDQG+5FROOHFWHGGXULQJ(77UZLOOEH VXPPDUL]HGDWVSHFLILFWLPHSRLQWV EDVHOLQHSHDNDQGODVWPHDVXUHPHQW 'HVFULSWLYH VXPPDULHVZLOOEHSURYLGHGIRUWKHPD[LPXPFKDQJHIURPEDVHOLQHLQ6%3DQG+5RQ GD\SRVWGRVHGXULQJ(77UIRU&RXQWU\6SHFLILF6XSSOHPHQWFRXQWULHV

$QWLERG\)RUPDWLRQ 7KHLQFLGHQFHDQGSHUFHQWDJHRIVXEMHFWVZKRGHYHORSDQWL$0*DQWLERGLHV ELQGLQJ DQGLISRVLWLYHQHXWUDOL]LQJ DWDQ\WLPHZLOOEHWDEXODWHGE\WUHDWPHQWJURXS

([SRVXUHWR&RQFRPLWDQW0HGLFDWLRQ 1XPEHUDQGSURSRUWLRQRIVXEMHFWVUHFHLYLQJWKHUDSLHVRILQWHUHVWZLOOEHVXPPDUL]HGE\ FDWHJRU\IRUHDFKWUHDWPHQWJURXSDVFRGHGE\WKH:RUOG+HDOWK2UJDQL]DWLRQ'UXJ :+2'58* GLFWLRQDU\6HH$SSHQGL['IRUDOLVWRIVHOHFWHGPHGLFDWLRQVDQGWKHLU JURXSLQJV

3KDUPDFRNLQHWLF$QDO\VLV $OO3.UHODWHGWDEOHVILJXUHVOLVWLQJVDQGRWKHUGHOLYHUDEOHVZLOOEHJHQHUDWHGE\3.'0 6HUXP$0*FRQFHQWUDWLRQVZLOOEHVXPPDUL]HGXVLQJGHVFULSWLYHVWDWLVWLFV

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

$GGLWLRQDO6DIHW\(QGSRLQWVIRU&RXQWU\6SHFLILF6XSSOHPHQW &RXQWULHV 7KLVVHFWLRQLVIRUFRXQWULHVWKDWZHUHRULJLQDOO\DOLJQHGZLWK(89+3 (XURSHDQ8QLRQ 9ROXQWDU\+DUPRQL]DWLRQ3URFHGXUH UHTXLUHPHQWV7KHVHFRXQWULHVDUHOLVWHGLQWKH &RXQWU\6SHFLILFVXSSOHPHQWVRIWKHSURWRFRO LH&]HFK5HSXEOLF/DWYLD5RPDQLD %XOJDULDDQG3RODQG

$IWHUWKHHQGRI(77DOOVXEMHFWVZLOOEHIROORZHGDWWKHVLWHIRUDWOHDVWKRXUV$WWKH HQGRIWKHKRXUIROORZXSSHULRGWKHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHG

x OHDGUHVW(&*LQDVLWWLQJSRVLWLRQ x %ORRGSUHVVXUHPHDVXUHPHQWLQDVLWWLQJSRVLWLRQ x %ORRGVDPSOLQJIRUPHDVXUHPHQWRIFDUGLDFELRPDUNHU WURSRQLQ,

$GGLWLRQDOYLVLWVIRUDQWL$0*DQWLERG\ 'D\3UHGRVHZHHNDQGZHHN DQG &6656 YLVLWYLVLWYLVLWDQGZHHN ZLOOEHFROOHFWHGIRUFRXQWULHVOLVWHGLQ &RXQWU\6SHFLILF6XSSOHPHQW

7KHVHDGGLWLRQDOGDWDZLOOEHLQFOXGHGLQWKHDQDO\VLV

&KDQJHV)URP3URWRFROVSHFLILHG$QDO\VHV 7KHUHDUHQRFKDQJHVWRWKHSURWRFROVSHFLILHGDQDO\VHV

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

/LWHUDWXUH&LWDWLRQV5HIHUHQFHV x 2¶%ULHQ5* ³$6LPSOH7HVWIRU9DULDQFH(IIHFWVLQ([SHULPHQWDO 'HVLJQV´3V\FKRORJLFDO%XOOHWLQ± x )UHXQG5-/LWWHOO5&DQG6SHFWRU3& 6$66\VWHPIRU/LQHDU 0RGHOV(GLWLRQ&DU\1&6$6,QVWLWXWH,QF x *LEERQV-'DQG&KDNUDERUWL6 1RQSDUDPHWULF6WDWLVWLFDO,QIHUHQFH 7KLUG(GLWLRQ1HZ

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

'DWD1RW&RYHUHGE\7KLV3ODQ 7KHUHDUHQRSODQVWRVSHFLILFDOO\DQDO\]HRUVXPPDUL]HWKHIROORZLQJGDWDSRLQWV

x3. x 'DWDIRUELRPDUNHUGHYHORSPHQW

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

$SSHQGLFHV

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 25

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 24

Appendix A. Post-baseline Study Visits Since the actual visit for a subject may not exactly coincide with their targeted visit date, the actual visit date is mapped to the study visit as following. The study day window will be utilized to define study visit for labs, antibody, vital signs and physical measurements collected at office visits.

Study Visit Target Day Study Day

Week 4 29 16-43

Week 8 57 44-71

Week 12 85 72 to Min (EOS Date, last IP dose date + 84 days)

Note: 1. If more than one visit (including unscheduled visits, ie, CPEVENT = ‘UNSCHED’) fall within the same defined window, scheduled visit will be used regardless of the distance from the target day. Unscheduled visit will only be used when there is no scheduled visit in the defined window. The closest visit to the target day among the same type of visit (scheduled vs. unscheduled) will be considered for analysis. If two assessment dates are equidistant from the target date, the latter visit will be considered for analysis.

2. For Country Specific Supplement countries, CSSRS and ECG data are collected at week 2 (target day 14), corresponding to study day 1-28.

3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

$SSHQGL[%7HFKQLFDO'HWDLODQG6XSSOHPHQWDO,QIRUPDWLRQ5HJDUGLQJ6WDWLVWLFDO 3URFHGXUHVDQG3URJUDPV &RGH)UDJPHQWV

6HFWLRQ CCI 3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH

CCI 3URGXFW $0* &OLQLFDO6WXG\5HSRUW3ULPDU\$QDO\VLV 'DWH $SULO 3DJH

3URGXFW$0* 6WDWLVWLFDO$QDO\VLV3ODQ 'DWH-DQXDU\ 3DJH CCI

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 29

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 28

Appendix C. Reference Values/Toxicity Grades Adverse event severity and laboratory parameters are graded based on National Cancer Institute (NCI) Common Toxicity Criteria version 4 or higher, which is available at the following: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 14_QuickReference_5x7.pdf

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 30

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 29

Appendix D. Concomitant Medications

Group Medications

Beta-blockers BETA BLOCKING AGENTS ADAPROLOL ANTIARRHYTHMIC AGENTS BETA BLOCKING AGENTS BUFETOLOL BUFETOLOL HYDROCHLORIDE DILEVALOL DILEVALOL HYDROCHLORIDE ISAMOLTAN MABUTEROL MABUTEROL HYDROCHLORIDE MOPROLOL MOPROLOL HYDROCHLORIDE NADOXOLOL NADOXOLOL HYDROCHLORIDE NIFENALOL NIFENALOL HYDROCHLORIDE OBERADILOL ALPRENOLOL ALPRENOLOL BENZOATE ALPRENOLOL HYDROCHLORIDE BETA BLOCKING AGENTS, NON-SELECTIVE BETAMED /02298401/ BLOCOTIN /00716001/ BOPINDOLOL BOPINDOLOL FUMARATE BOPINDOLOL MALONATE BUCINDOLOL BUCINDOLOL HYDROCHLORIDE BUFURALOL BUFURALOL HYDROCHLORIDE BUNITROLOL BUNITROLOL HYDROCHLORIDE

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 31

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 30

BUPRANOLOL BUPRANOLOL HYDROCHLORIDE CARAZOLOL CARTEOLOL CARTEOLOL HYDROCHLORIDE CLORANOLOL CLORANOLOL HYDROCHLORIDE CLOTAS PLUS EXAPROLOL EXAPROLOL HYDROCHLORIDE INDENOLOL INDENOLOL HYDROCHLORIDE MEPINDOLOL MEPINDOLOL SULFATE METIPRANOLOL METIPRANOLOL HYDROCHLORIDE NADOLOL NIPRADOLOL OXPRENOLOL OXPRENOLOL HYDROCHLORIDE PENBUTOLOL PENBUTOLOL SULFATE PINDOLOL PRONETALOL PRONETALOL HYDROCHLORIDE PROPRANOLOL PROPRANOLOL HYDROCHLORIDE PROPRANOLOL PHENOBARBITAL SOLOPOSE BETA SOTACOR/ASA SOTALOL SOTALOL HYDROCHLORIDE TENSYN PLUS TERTATOLOL TERTATOLOL HYDROCHLORIDE TILISOLOL

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 32

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 31

TILISOLOL HYDROCHLORIDE TIMOLOL TIMOLOL HEMIHYDRATE TIMOLOL MALEATE TIMOLOL MALEATE, R-ENANTIOMER TIMOLOL MALEATE, S-ENANTIOMER ZEPRO /02777801/ ACEBUTOLOL ACEBUTOLOL HYDROCHLORIDE ATENOLOL ATENOLOL HYDROCHLORIDE BELOC /01739801/ BETA BLOCKING AGENTS, SELECTIVE BETAXOLOL BETAXOLOL HYDROCHLORIDE BEVANTOLOL BEVANTOLOL HYDROCHLORIDE BISOBLOCK PLUS BISOPROLOL BISOPROLOL FUMARATE BUCUMOLOL BUCUMOLOL HYDROCHLORIDE BUTIDRINE CELIPROLOL CELIPROLOL HYDROCHLORIDE DEXNEBIVOLOL DIACETOLOL DIACETOLOL HYDROCHLORIDE EPANOLOL ERAMID ESATENOLOL ESMOLOL ESMOLOL HYDROCHLORIDE LANDIOLOL LANDIOLOL HYDROCHLORIDE LEVONEBIVOLOL

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 33

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 32

METOPROLOL METOPROLOL FUMARATE METOPROLOL SUCCINATE METOPROLOL TARTRATE METOPROLOL W/MORPHINE METPURE ST NEBIVOLOL NEBIVOLOL HYDROCHLORIDE PAFENOLOL PRACTOLOL SELOKEN ZOC/ASA TALINOLOL TOLAMOLOL TOLAMOLOL HYDROCHLORIDE ZOLAT /03453901/ ALPHA AND BETA BLOCKING AGENTS AMINO ACIDS NOS W/CAFFEINE/CARVEDILOL/CHOLINE

AMOSULALOL AMOSULALOL HYDROCHLORIDE AROTINOLOL AROTINOLOL HYDROCHLORIDE CARVEDILOL CARVEDILOL HYDROCHLORIDE CARVEDILOL PHOSPHATE HEMIHYDRATE LABETALOL LABETALOL HYDROCHLORIDE MEDROXALOL MEDROXALOL HYDROCHLORIDE PROXODOLOL BETA BLOCKING AGENTS AND THIAZIDES BETA BLOCKING AGENTS, NON-SELECTIVE, AND THIA BETACENTYL CORGARETIC CORINDOCOMB

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 34

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 33

DOCIDRAZIN HIPERDON /00991401/ INDERETIC INDERIDE PRESTYL SOTAZIDE TIMOLIDE TORRAT TRASIDREX TRI-TORRAT VISKAZIDE ATENOLOL W/HYDROCHLOROTHIAZIDE ATPURE-D BELOC-ZOC COMP BETA BLOCKING AGENTS, SELECTIVE, AND THIAZIDE BISELECT /01166101/ BISOPROLOL W/HYDROCHLOROTHIAZIDE /06833601/ CO-BETALOC NEATENOL DIU NEATENOL DIUVAS NEBICARD-H RANEZIDE SECADREX SECTRAZIDE /00774201/ SELOKEN COMP. TRELOC ALPHA AND BETA BLOCKING AGENTS AND THIAZIDES CO-DILATREND NORMOZIDE /00897401/ BETA BLOCKING AGENTS AND OTHER DIURETICS BETA BLOCKING AGENTS, NON-SELECTIVE/90118901/ BETARELIX HIPERDON /00991401/

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 35

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 34

LASIPRESSIN SANDORETIC SPIROPROP TRASITENSIN TREPRESS VISKALDIX BETA BLOCKING AGENTS, SELECTIVE, AND OTHER DI INDAPAMIDE W/NEBIVOLOL HYDROCHLORIDE LOPRESORETIC NOR-PA SALI-PRENT SELECTURON TEKLO TENORETIC TRI-NORMIN VINICOR D ALPHA AND BETA BLOCKING AGENTS AND OTHER DIUR CARVEDILOL + CLORTALIDONA TRANDIUR BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIU BETA BLOCKING AGENTS, NON-SELECTIVE, THIAZIDE CARDIOTENSIN /01682501/ DOCITEREN DOCITON 80 DYTIDE H MODUCREN BETA BLOCKING AGENTS, SELECTIVE, THIAZIDES AN KALTEN KERLIDEX BETA BLOCKING AGENTS AND VASODILATORS BETA BLOCKING AGENTS, NON-SELECTIVE, AND VASO BETA-INTENSAIN NITRISKEN NITRO-OBSIDAN

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 36

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 35

OXYCARDIN /00391901/ PRIZIDILOL PRIZIDILOL HYDROCHLORIDE PRIZIDILOL HYDROCHLORIDE ANHYDROUS BETA BLOCKING AGENTS, SELECTIVE, AND VASODILA MET XL R METOPROLOL W/RAMIPRIL NEBICARD V STARPRESS R BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSI BETA BLOCKING AGENTS, NON-SELECTIVE/90119501/ BETADIPRESAN INDUCOR INDUCOR D OBSILAZIN REDUPRESS /03518901/ TRASIPRESSOL TRIMECRYTON AMLODIPINE W/METOPROLOL AMLODIPINE W/NEBIVOLOL AMLONG-A ARBITEL MT ATPURE-SA BELNIF BETA BLOCKING AGENTS, SELECTIVE, AND OTHER AN BETAFIT AM BETAONE AM CARDIF BETA CARDIORETIC A CARVEDIPINA D CILNIDIPINE W/METOPROLOL SUCCINATE CILNIPAR M CONCOR AM

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 37

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 36

CONCORAM FELODIPINE W/METOPROLOL FIXOCARD LOTENSYL AT MET XL AM METONCE AM METOPROLOL W/TELMISARTAN MODILOC NEBI AM NEBICARD-SM NIF-TEN NITRENOL NUSAR-ATN OLSAR M RASOTAN BETA TELISTA MT TONORMA TREDALAT ADAPROLOL ALCON BETAXOLOL AZARGA BAMOSIRAN BEFUNOLOL BEFUNOLOL HYDROCHLORIDE BETA BLOCKING AGENTS BETALOL /03186001/ BETAXOLOL BETAXOLOL HCL W/PILOCARPINE HCL BETAXOLOL HYDROCHLORIDE BETAXOLOL W/PILOCARPINE BLOCANOL /01100601/ BRIMONIDINE TARTRATE W/TIMOLOL BRIMONIDINE W/TIMOLOL

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 38

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 37

CARPILO CARTEOL /00853401/ CARTEOLOL CARTEOLOL HYDROCHLORIDE CARTEOPIL COMBIGAN COSOPT DORZOLAMIDE W/TIMOLOL DORZOPT /06421101/ DUOTRAV ELAZOP GANFORT GLAUTIMOL /06108601/ KRITANTEK OFTENO KRYTANTEK OFTENO LEVOBUNOLOL LEVOBUNOLOL HYDROCHLORIDE METIPRANOLOL METIPRANOLOL HYDROCHLORIDE MOPROLOL MOPROLOL HYDROCHLORIDE NIPRADOLOL NORMOGLAUCON /01482401/ PILOBLOQ PILOFLAX PINDOLOL PROXODOLOL PROXOPHELIN RIPIX TAFLUPROST W/TIMOLOL MALEATE TIMED TIMOLO TIMOLOL

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 39

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 38

TIMOLOL HEMIHYDRATE TIMOLOL MALEATE TIMOLOL MALEATE, R-ENANTIOMER TIMOLOL MALEATE, S-ENANTIOMER TIMPILO VISTAGAN /00844001/ XALACAR-T XALACOM

Nitrates ADOCOR /01266201/ ANGIOCARDYL N ANGOR ASPITRATE G BIDIL CAFINITRINA /00702101/ CAFINITRINA /07893501/ CAFINITRINA RETARD CARDIACAP A CARDIOSEDANTOL CEFAVORA COR /08009401/ CONVALLARIA MAJALIS W/GLYCERYL TRINITRATE/LEV CORANGIL DILCORAN /00119101/ ERITRITYL TETRANITRATE ERYTHROMIN /01950501/ EUCARDIN GLYCERYL TRINITRATE GLYCERYL TRINITRATE, COMBINATIONS GOVIL IMAZIN XL ISO-NITROLINGUAL ISOSORBIDE DINITRATE ISOSORBIDE DINITRATE W/SODIUM CHLORIDE

ISOSORBIDE DINITRATE, COMBINATIONS ISOSORBIDE MONONITRATE

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 40

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 39

KORDILAT MANNITOL HEXANITRATE METHYLPROPYLPROPANEDIOL DINITRATE MYANGIN MYOCARDON /00091601/ MYOCARDON /02403401/ MYOCARDON /03439401/ MYOCORIL NATIROSE /01832701/ NEO-AKTAL NITRANGIN COMPOSITUM NITRAPAMIL NITRIC OXIDE NITRO-CRATAEGUTT NITRODURAT NITROGLIN NITROGLYCERIN COMP. NITROPENT COMP. NITROTHESAL NITROUS ETHER SPIRIT NUNZANGIL ORGANIC NITRATES PENTAERITHRITYL TETRANITRATE PENTANEURAL PENTOXYLON PENTRINITROL PENTRIUM PROPATYLNITRATE SEDA-ILDAMEN SORBANGIL COMP. SPASMOCOR STENODILATE STENOPTIN TENITRAMINE THEOPENTRIT THEOPENTRIT PAPAV

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 41

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 40

TRINITRINE CAFFEINE TROLNITRATE TROLNITRATE PHOSPHATE VISANOCOR VISANOCOR N

VERAPAMIL Calcium channel VERAPAMIL HYDROCHLORIDE blockers ISOPTIN S TALUVIAN /00149301/ LIDOFLAZINE PERHEXILINE PERHEXILINE MALEATE GRADULON FENDILINE FENDILINE HYDROCHLORIDE NIFEDIPINE DILTIAZEM DILTIAZEM HYDROCHLORIDE DILTIAZEM MALATE DIGO-SENSIT STENOPTIN CORDICHIN ELTHON /00603601/ NICARDIPINE NICARDIPINE HYDROCHLORIDE GALLOPAMIL GALLOPAMIL HYDROCHLORIDE FELODIPINE ISRADIPINE TIAPAMIL SALI-ADALAT BEPRIDIL BEPRIDIL HYDROCHLORIDE MONOHYDRATE NITRENDIPINE TREDALAT NISOLDIPINE NIF-TEN BELNIF NIMODIPINE VERATIDE

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 42

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 41

OXODIPINE AMLODIPINE AMLODIPINE BESILATE AMLODIPINE MALEATE AMLODIPINE MESILATE AMLODIPINE CAMSILATE AMLODIPINE OROTATE S AMLODIPINE NICOTINATE AMLODIPINE ADIPATE NILVADIPINE MANIDIPINE MANIDIPINE HYDROCHLORIDE LACIDIPINE BENIDIPINE BENIDIPINE HYDROCHLORIDE MODILOC EFONIDIPINE EFONIDIPINE HYDROCHLORIDE SALOPTASIN BARNIDIPINE BARNIDIPINE HYDROCHLORIDE UDRAMIL MIBEFRADIL MIBEFRADIL HYDROCHLORIDE LEXXEL TECZEM /01366001/ LERCANIDIPINE LERCANIDIPINE HYDROCHLORIDE CILNIDIPINE VERACAPT UNIMAX ADIZEM-XL PLUS ANIPAMIL TILDIAZIDE OCADRIK /01507301/ AZELNIDIPINE ENEAS NIMOREAGIN /01616501/ AMLODIPINE W/BENAZEPRIL AMLODIPINE BESYLATE W/BENAZEPRIL AMLODIPINE W/VALSARTAN

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 43

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 42

AMLODIPINE W/HYDROCHLOROTHIAZIDE AMLONG-A CADUET ARANIDIPINE SINERGEN HYDROCHLOROTHIAZIDE W/VERAPAMIL LOTAR /02225901/ AMLOPRES L RIODIPINE DIOVAN AMLO MET XL AM TONORMA FIXOCARD LOTRIX /03460001/ NIMOSOMAZINA REDUPRESS /03518901/ NAPRIX A ASOMEX-D CARDIF BETA LOTENSYL AT ATPURE-SA NEBICARD-SM ACEDIP CLEVIDIPINE ANTROLIN CARDIORETIC A NITRENOL ETIPRESS-D MAXIDIPIN DIU NIFEDIP D CARVEDIPINA D INDUCOR INDUCOR D BETAONE AM AZOR /06230801/ AMLOZAAR-H TWYNSTA TELSAR-A DIOVAN TRIPLE OROSPREVENT COVERAM

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 44

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 43

NEMOCEBRAL PLUS LEVAMLODIPINE LEVAMLODIPINE BESILATE LEVAMLODIPINE MALATE LEVAMLODIPINE MALEATE FELODIPINE W/METOPROLOL NIFEDIPINE W/TELMISARTAN PONTUC DIRONORM COZAAR XQ BENITEC A /06541301/ OLMESAFE AM CONCOR AM CANDESAR A AMLODIPINE W/ATORVASTATIN TRIBENZOR ATACAND DUO AMLODIPINE MALEATE W/BENAZEPRIL HYDROCHLORIDE RASILEZ AMLO AMTAS PRP FLORDIPINE NIGULDIPINE NORVERAPAMIL AZIDOPINE IGANIDIPINE AMLODIPINE W/BENAZEPRIL HYDROCHLORIDE VIVACE /06864501/ FENSARTAN UNIMAX AMTURNIDE AVOTIN AZELNIDIPINE W/OLMESARTAN MEDOXOMIL AMLODIPINE BESILATE W/ATORVASTATIN CALCIUM TR MOXOVAS A OLMAT AMH TEKAMLO /07156301/ AMLODIPINE W/HYDROCHLOROTHIAZIDE/VALSARTAN NATRILAM BETAFIT AM CILACAR T

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 45

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 44

MODLIP AM NEBI AM DILVAS AM R PRIL AM AMLODAC D TELMICHEK AH RASITRIO DUPLECOR PERINDOPRIL ARG/AMLODIPINE FISHER CONCORAM AMLATOR TAH ENALAPRIL W/NITRENDIPINE APROVASC COROVAL B ZANERIL ENALAPRIL W/LERCANIDIPINE AMLODIPINE W/OLMESARTAN ANOBLISS ASOMEX TM RAMI ASOMEX CILNIPAR M ASOMEX LTH METONCE AM ROSUCOR PLUS AMLODIPINE W/NEBIVOLOL AMLODIPINE W/INDAPAMIDE/PERINDOPRIL LERCANIDIPINE HYDROCHLORIDE W/VALSARTAN LEVAMLODIPINE BESILATE W/VALSARTAN AMLODIPINE W/CHLORTALIDONE/LOSARTAN POTASSIUM CILNIDIPINE W/OLMESARTAN MEDOXOMIL AMLODIPINE OROTATE W/VALSARTAN HYDROCHLOROTHIAZIDE W/LEVAMLODIPINE BESILATE AMLODIPINE MESILATE W/HYDROCHLOROTHIAZIDE/VAL AMLODIPINE W/CHLORTALIDONE/OLMESARTAN MEDOXOM AMLODIPINE W/CHLORTALIDONE/TELMISARTAN AMLODIPINE BESILATE W/INDAPAMIDE/PE/08715301/ AMLODIPINE BESILATE W/PERINDOPRIL TOSILATE AMLODIPINE BESILATE W/INDAPAMIDE/PE/08717501/

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 46

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 45

CILNIDIPINE W/VALSARTAN AMLODIPINE BESILATE W/AZILSARTAN ATORVASTATIN CALCIUM W/LEVAMLODIPINE BESILATE CILNIDIPINE W/METOPROLOL SUCCINATE AMLODIPINE W/METOPROLOL AMLODIPINE BESILATE W/CANDESARTAN CILEXETIL/H AMLODIPINE W/LISINOPRIL/ROSUVASTATIN AMLODIPINE W/ROSUVASTATIN AMLODIPINE ADIPATE W/VALSARTAN AMLODIPINE W/CLOPIDOGREL BISULFATE CHLORTALIDONE W/CILNIDIPINE/TELMISARTAN AMLODIPINE OROTATE W/OLMESARTAN MEDOXOMIL CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINL DIHYDROPYRIDINE DERIVATIVES SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIREC PHENYLALKYLAMINE DERIVATIVES BENZOTHIAZEPINE DERIVATIVES NON-SELECTIVE CALCIUM CHANNEL BLOCKERS

Ranolazine Ranolazine

CAPTOPRIL ACE inhibitors ENALAPRIL ENALAPRIL MALEATE CAPOZIDE PERINDOPRIL PERINDOPRIL ERBUMINE PERINDOPRIL ARGININE PERINDOPRIL TOSILATE QUINAPRIL QUINAPRIL HYDROCHLORIDE CILAZAPRIL CILAZAPRIL MONOHYDRATE RAMIPRIL LISINOPRIL LISINOPRIL DIHYDRATE VASERETIC SPIRAPRIL SPIRAPRIL HYDROCHLORIDE

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 47

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 46

BENAZEPRIL BENAZEPRIL HYDROCHLORIDE FOSINOPRIL FOSINOPRIL SODIUM ENALAPRILAT ZOFENOPRIL ZOFENOPRIL CALCIUM ALACEPRIL DELAPRIL DELAPRIL HYDROCHLORIDE GEZOR TRANDOLAPRIL CIBADREX SALUTEC ARELIX ACE DYNORM PLUS QUINAPRILAT QUINAPRILAT HYDRATE TEMOCAPRIL TEMOCAPRIL HYDROCHLORIDE IMIDAPRIL IMIDAPRIL HYDROCHLORIDE MOEXIPRIL MOEXIPRIL HYDROCHLORIDE UDRAMIL ELIDIUR LEXXEL TECZEM /01366001/ VERACAPT LASITACE DELAPRIDE PRIMOX PLUS UNIMAX BI PREDONIUM BENAZEPRILAT PENTOPRIL IDRAPRIL MOVELTIPRIL CERONAPRIL TRANDOLAPRILAT UTIBAPRIL ZABICIPRIL

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 48

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 47

LIBENZAPRIL DINAPRES OCADRIK /01507301/ ENEAS CARACE PLUS /01613901/ AMLODIPINE W/BENAZEPRIL AMLODIPINE BESYLATE W/BENAZEPRIL ALENDRONATE SODIUM W/QUINAPRIL HYDROCHLORIDE SINERGEN AMLOPRES L LORAM-H ENZIX LOTRIX /03460001/ ARBITACE ORAS /03528201/ TERAM NAPRIX A ACEDIP M 100240 VASCORIDE CARDIO-PRES D CARSIPRIL D RAMICAR D CVPILL NORMATEN /06267401/ ATOCOR-R MODLIP-CAD OLMY-R ADPACE BIFRIL PLUS PERINDO COMBI COVERAM PRETERAX ARGININE ZESTORETIC INDAPAMIDE W/PERINDOPRIL HYDROCHLOROTHIAZIDE W/QUINAPRIL FOSINOPRIL W/HYDROCHLOROTHIAZIDE ENAP-HL /06436201/ CAPTOPRIL W/ENALAPRIL DIRONORM POLYCAP ZOPRANOL PLUS

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 49

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 48

AMLODIPINE MALEATE W/BENAZEPRIL HYDROCHLORIDE AMTAS PRP CILAZAPRIL MONOHYDRATE W/HYDROCHLOROTHIAZIDE GEMOPATRILAT HYDROCHLOROTHIAZIDE W/MOEXIPRIL FASIDOTRIL UTIBAPRILAT MOEXIPRILAT MOEXIPRILAT HYDROCHLORIDE OMAPATRILAT AMLODIPINE W/BENAZEPRIL HYDROCHLORIDE BENAZEPRIL W/HYDROCHLOROTHIAZIDE VIVACE /06864501/ CAPTRAL ASA RAMEY D STARPRESS R DILVAS AM R PRIL AM VALZAAR R TERAM H METPURE AR PERINDOPRIL ARG/AMLODIPINE FISHER LOTRIAL VAS ENALAPRIL W/NITRENDIPINE SINCRONIUM /07912401/ COROVAL B ZANERIL ENALAPRIL W/LERCANIDIPINE RAMITORVA METOZ R MET XL R RAMI ASOMEX PERINDOPRIL TOSILATE/ INDAPAMIDE METOPROLOL W/RAMIPRIL SAMPATRILAT AMLODIPINE W/INDAPAMIDE/PERINDOPRIL GLIMEPIRIDE W/METFORMIN HYDROCHLORIDE/RAMIPRI ATORVASTATIN CALCIUM W/GLIMEPIRIDE//08698201/ AMLODIPINE BESILATE W/INDAPAMIDE/PE/08715301/ AMLODIPINE BESILATE W/PERINDOPRIL TOSILATE

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 50

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 49

AMLODIPINE BESILATE W/INDAPAMIDE/PE/08717501/ AMLODIPINE W/LISINOPRIL/ROSUVASTATIN TEMOCAPRILAT INDAPAMIDE HEMIHYDRATE W/PERINDOPRIL ARGININE ACE INHIBITORS, PLAIN ACE INHIBITORS, COMBINATIONS ACE INHIBITORS AND CALCIUM CHANNEL BLOCKERS ACE INHIBITORS

LOSARTAN Angiotensin LOSARTAN POTASSIUM receptor blockers HYZAAR TASOSARTAN SAPRISARTAN SAPRISARTAN POTASSIUM VALSARTAN IRBESARTAN IRBESARTAN HYDROCHLORIDE CO-DIOVAN EPROSARTAN EPROSARTAN MESILATE CANDESARTAN CANDESARTAN CILEXETIL KARVEA HCT BLOPRESS PLUS TELMISARTAN HYDROCHLOROTHIAZIDE W/LOSARTAN AMLODIPINE W/VALSARTAN OLMESARTAN OLMESARTAN MEDOXOMIL BENICAR HCT CANDESARTAN W/HYDROCHLOROTHIAZIDE LOTAR /02225901/ DIOVAN AMLO LORAM-H NUSAR-ATN ARBITACE ORAS /03528201/ TERAM DIOCOMB SI AZOR /06230801/ AMLOZAAR-H TWYNSTA TELSAR-A DIOVAN TRIPLE OLMY-R LOSAR BETA-H ADPACE

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 51

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 50

VALTURNA EMBUSARTAN PRITORPLUS EMESTAR PLUS NIFEDIPINE W/TELMISARTAN HYDROCHLOROTHIAZIDE W/OLMESARTAN COZAAR XQ PLEOTOR T BENITEC A /06541301/ OLMESAFE AM CANDESAR A TRIBENZOR ATACAND DUO ABITESARTAN RIPISARTAN AZILSARTAN AZILSARTAN MEDOXOMIL AZILSARTAN KAMEDOXOMIL POMISARTAN PRATOSARTAN FENSARTAN UNIMAX OLSAR M AZELNIDIPINE W/OLMESARTAN MEDOXOMIL OLMAT AMH AMLODIPINE W/HYDROCHLOROTHIAZIDE/VALSARTAN CO IRABEL CILACAR T INDITEL D ZIVAST L VALZAAR R NEBICARD V TERAM H RASOTAN BETA TELISTA MT TELMICHEK AH EDARBYCLOR FIMASARTAN FIMASARTAN POTASSIUM TRIHYDRATE TELROSE CTD L ARBITEL MT TAH APROVASC AMLODIPINE W/OLMESARTAN ERITEL CH OLMESAT ID ALISKIREN W/VALSARTAN METOZ L METOPROLOL W/TELMISARTAN

Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 52

Product: AMG 334 Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 51

ASOMEX TM OLMESAR AV ASOMEX LTH IRBESARTAN W/TRICHLORMETHIAZIDE FIMASARTAN POTASSIUM TRIHYDRATE W/HYDROCHLORO LERCANIDIPINE HYDROCHLORIDE W/VALSARTAN LEVAMLODIPINE BESILATE W/VALSARTAN AMLODIPINE W/CHLORTALIDONE/LOSARTAN POTASSIUM CHLORTALIDONE W/OLMESARTAN MEDOXOMIL CILNIDIPINE W/OLMESARTAN MEDOXOMIL AMLODIPINE OROTATE W/VALSARTAN AMLODIPINE MESILATE W/HYDROCHLOROTHIAZIDE/VAL ATORVASTATIN CALCIUM W/IRBESARTAN AMLODIPINE W/CHLORTALIDONE/OLMESARTAN MEDOXOM AMLODIPINE W/CHLORTALIDONE/TELMISARTAN OLMESARTAN MEDOXOMIL W/ROSUVASTATIN CALCIUM CILNIDIPINE W/VALSARTAN ROSUVASTATIN CALCIUM W/VALSARTAN AMLODIPINE BESILATE W/AZILSARTAN AMLODIPINE BESILATE W/CANDESARTAN CILEXETIL/H AMLODIPINE ADIPATE W/VALSARTAN CHLORTALIDONE W/CILNIDIPINE/TELMISARTAN AMLODIPINE OROTATE W/OLMESARTAN MEDOXOMIL SACUBITRIL W/VALSARTAN ANGIOTENSIN II ANTAGONISTS, PLAIN ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS AND CALCIUM

CHANNE

Web Analytics